| 000 | 01763 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516130059.0 | ||
| 264 | 0 | _c20131024 | |
| 008 | 201310s 0 0 eng d | ||
| 022 | _a1399-3062 | ||
| 024 | 7 |
_a10.1111/tid.12037 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTaimur, S | |
| 245 | 0 | 0 |
_aMicrobiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis. _h[electronic resource] |
| 260 |
_bTransplant infectious disease : an official journal of the Transplantation Society _cApr 2013 |
||
| 300 |
_a187-94 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAmyloidosis _xtherapy |
| 650 | 0 | 4 |
_aBacterial Infections _xdiagnosis |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aCross Infection _xetiology |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunoglobulin Light Chains |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelphalan _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMycoses _xdiagnosis |
| 650 | 0 | 4 |
_aMyeloablative Agonists _xadministration & dosage |
| 650 | 0 | 4 | _aPostoperative Complications |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aStem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 | _aTransplantation, Autologous |
| 700 | 1 | _aNader, C | |
| 700 | 1 | _aLloyd-Travaglini, C | |
| 700 | 1 | _aSeldin, D C | |
| 700 | 1 | _aSanchorawala, V | |
| 773 | 0 |
_tTransplant infectious disease : an official journal of the Transplantation Society _gvol. 15 _gno. 2 _gp. 187-94 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/tid.12037 _zAvailable from publisher's website |
| 999 |
_c22383986 _d22383986 |
||